Filing search / Incannex Healthcare Limited / "Engagement"

PRE 14A

IXHL Incannex Healthcare Limited

31 Oct 24

Preliminary proxy

4:10pm

of an audit or non-audit service may be given as a general pre-approval, as part of the audit committee’s approval of the scope of the engagement of our

10-K

2024 FY

IXHL Incannex Healthcare Limited

30 Sep 24

Annual report

7:30am

service may be given as a general pre-approval, as part of the audit committee’s approval of the scope of the engagement of our independent registered

8-K

EX-10.1

IXHL Incannex Healthcare Limited

10 Sep 24

Entry into a Material Definitive Agreement

7:30am

of Investor’s customary due diligence and legal fees (and will provide proof of any retainer payments and engagement letters). In consideration

S-1/A

IXHL Incannex Healthcare Limited

17 Jul 24

IPO registration (amended)

8:47am

of representations and warranties contained in our engagement letter with the joint placement agents. We have also agreed to contribute to payments

S-1/A

EX-10.9

IXHL Incannex Healthcare Limited

17 Jul 24

IPO registration (amended)

8:47am

representatives (1) has any duties or obligations other than those specifically set forth herein or in the engagement letter, dated as [March 4, 2024 … among the Company and Jones] (the “Engagement Letter”) or in the Placement Agency Agreement, dated as of the date hereof, by and between the Company

S-1

zj3ouwd

3 Jul 24

IPO registration

6:29am

8-K

EX-10.1

40hg7

5 Mar 24

Departure of Directors or Certain Officers

6:11am

10-Q

EX-10.14

5l40xia8

14 Feb 24

Quarterly report

6:16am

8-K

hymdxw2c

15 Dec 23

Changes in Registrant's Certifying Accountant

6:09am

8-K

EX-10.1

4rzd6yqmxv1j

29 Nov 23

Entry into a Material Definitive Agreement

4:36pm

8-K

EX-3.2

mkgoxi67 s08dtd

29 Nov 23

Entry into a Material Definitive Agreement

4:36pm

6-K

EX-99.1

asjid

1 Sep 23

Report of Foreign Private Issuer

8:43am

6-K

EX-99.1

lrwooitzb1yqtzn8tg

1 Sep 23

Report of Foreign Private Issuer

12:00am

6-K

EX-99.1

y13tn lp9aylt29l

31 Jul 23

Incannex Provides Access to Financial Advisory Firm to Shareholders for Advice Pertaining to Transition from ASX to Nasdaq

7:34pm

6-K

EX-99.1

ronfu8pi w0c

18 Jul 23

Incannex engages Fortrea to Manage its FDA IND Opening Phase 2/3 Clinical Trial Investigating IHL-42X for Treatment of Obstructive Sleep Apnoea

6:04am

6-K

EX-99.1

5a77q7j

3 May 23

Report of Foreign Private Issuer

6:05am

20-F

c6y6visf4p8k czj

28 Oct 22

Annual report (foreign)

6:31am

20-F

EX-4.11

vx13oek2zklbfc04aww

28 Oct 22

Annual report (foreign)

6:31am